



Date: 07-10-2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

Scrip Code: 526075

Subject: Announcement regarding Appointment of Chief Financial Officer

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Rekvina Laboratories Limited ("the Company"), at its meeting held on 07th October, 2026, has approved the appointment of Mr. Subrata Samanta as the Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from 07th October, 2026.

Mr. Subrata Samanta has confirmed that he is not debarred from holding the office of Chief Financial Officer by virtue of any order of SEBI or any other statutory authority.

The Board Meeting commenced at 06:50 p.m. and concluded at 7:15 p.m.

You are requested to kindly take the above information on record.

Thanking you,

For Rekvina Laboratories Limited
SHAH
SURBHIT
MUKESHBHAI
Digitally signed by
SHAH SURBHIT
MUKESHBHAI
Date: 2026.10.07
19:26:07 +05'30'
DIN: 01993300

CIN: L24231GJ1988PLC01145

Regd. Office: 3rd floor 5 Laxmi Society, B/h Baroda Heart Institute, O.P. Road, Vadodara – 390007

Email Id: info@rekvinalaboratories.com, rekvinalimited@gmail.com

Cont. No.: 0265-2362966



The requisite details pursuant to Regulation 30 of the SEBI Listing Regulations are as follows:

Particulars	Details
Name	Mr. Subrata Samanta
Designation	Chief Financial Officer (CFO) & Key Managerial Personnel
Date of Appointment	07-10-26
Reason for Appointment	Appointment of Chief Financial Officer
Profile	Subrata Samanta is a seasoned Finance and Costing professional with 20+ years of experience in Accounting, Finance, Costing, Budgeting, MIS, Taxation, Cost Audit and Financial Planning. He has worked with reputed multinational and Indian organizations including GNFC, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Intas Pharmaceuticals, RPG Life Sciences, Valmont Industries, Hindustan Lever and PricewaterhouseCoopers. He has extensive experience in SAP FICO, product costing, cost accounting, budgeting, financial reporting, cash-flow management, cost audit, due diligence, MIS and statutory compliances. He has also played key roles in SAP implementations, acquisition and integration of manufacturing facilities, activity-based costing, R&D costing and development of costing and accounting systems. He has served in senior finance roles, including Chief Manager (Finance) at Gujarat Narmada Valley Fertilizers & Chemicals Limited (GNFC), with responsibility for accounting operations, budgeting, costing, financial analysis, treasury, cost audit, taxation, banking, compliance and management reporting. He holds an M.Com. from Calcutta University and is an Associate Cost and Management Accountant (ACMA). His strong combination of financial, costing, ERP and management experience enables him to contribute effectively to strategic financial management and operational cost optimisation.
Disclosure of relationship between Directors	Not Applicable
Information as required under circular No. LIST/COMP/14/ 2018-19 and NSE/CML/2018/ 24 dated June 20, 2018 issued by BSE and NSE respectively	Not Applicable

CIN: L24231GJ1988PLC01145

Regd. Office: 3rd floor 5 Laxmi Society, B/h Baroda Heart Institute, O.P. Road, Vadodara – 390007

Email Id: info@rekvinlaboratories.com, rekvinlimited@gmail.com

Cont. No.: 0265-2362966